ISELIN, N.J., May 11 /PRNewswire-FirstCall/ -- Pharmos Corporation , which recently entered into a definitive agreement to acquire (subject to stockholder approval and other closing conditions), Vela Pharmaceuticals Inc. announced today that it will present at the Rodman & Renshaw Third Annual Healthcare Conference on Monday, May 15, 2006 at 10:05 AM Eastern Time.
Haim Aviv, PH.D., Chairman & CEO, will provide an update on the Company's business. A webcast of Pharmos' presentation will be available at http://wsw.com/webcast/rrshq8/pars/ and will be archived for a 90-day period after the conference.
About Pharmos Corporation
Pharmos discovers and develops novel therapeutics to treat a range of indications, including neurological and inflammatory disorders. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds. Cannabinor, the lead CB2-selective receptor agonist candidate, is scheduled for Phase 2 testing in pain indications during 2006. Other compounds from Pharmos's proprietary synthetic cannabinoid library are in preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, and other disorders.
Pharmos CorporationCONTACT: Pharmos U.S., Gale Smith, +1-732-452-9556, or Pharmos Israel,Irit Kopelov, +011-972-8-940-9679
Web site: http://www.pharmoscorp.com/
